Ann: Annual Report to Shareholders, page-2

Had a quick look at the Annual Report but could not see anything in particular to trigger the share price jump. Maybe just brownian motion?

Did see that their revenue, mostly from personal tests, of about $4.6m for FY22 which is up 25% from FY21 with a heavy back-end bias. They also say that this trend is continuing into FY23. The glass half full read of that is that growth in sales accelerated - second derivative - leading into June this year and that that increase in growth continues. Second derivatives are great!! Anyway we will find out in the next few days what Q1FY23 was like for personal test sales.